Lilly's Oral GLP-1 Wins China Approval, First Pill in a Market Seen at $4.5B
LLY sits 71% above its 52-week low of $850.51.
Summary
China approved orforglipron for chronic weight management, making Lilly the first company with a GLP-1 obesity pill in the country — previously only injectables were cleared there. JP Morgan projects China's GLP-1 weight-loss market at 30 billion yuan ($4.5 billion) in five to seven years, versus roughly 3-4 billion yuan ($449.75 million-$599.66 million) today. The edge is timing: Lilly gets an oral option in front of Novo Nordisk, Pfizer and Innovent in the world's second-largest pharma market. Pfizer already has its ecnoglutide injection approved in China since March, so the competitive field is filling in fast. Lilly shares are up 33.74% year-to-date and traded at $1,462.18 premarket, near the 52-week high of $1,460.
At the time of this announcement, LLY was trading at $1,452.70 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.4T. The 52-week trading range was $850.51 to $1,460.00. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Benzinga.